Review





Similar Products

cd31 microbeads  (Miltenyi Biotec)
96
Miltenyi Biotec cd31 microbeads
Glioma‐intrinsic HEXB promoted Endo‐MT changes of ECs. (A) Survival of GBM patients received bevacizumab treatment with different HEXB expression in GSE79671 (log‐rank test). (B) Survival of GBM patients received bevacizumab treatment with different HEXB expression in GSE72951 (log‐rank test). (C) The rate of response patients was lower in GBM patients with high HEXB expression in GSE72951 (Patients with a survival time superior to the median survival of the standard treatment were defined as the responder group, whereas those with a shorter survival time were defined as the non‐responder group). (D) The analysis of migration ability of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (E) Permeability changes of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (F) Immunofluorescence staining image of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (G) Western blot results of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (H) PCR results of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (I) Flow cytometry of <t>CD31</t> + cells in tumors from GSC1‐bearing mice. (J) Flow cytometry of CD31 + cells in tumors from GSC21‐bearing mice. (Date were presented as means ± standard deviations, * indicates p ≤ 0.05, ** indicates p < 0.01, **** indicates p < 0.0001.).
Cd31 Microbeads, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd31+mouse/CD31+MicroBeads%2C+mouse/pmc13650030-88-1-4
Average 96 stars, based on 1 article reviews
cd31 microbeads - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
mouse/rat cd31/pecam-1 alexa fluor® 488-conjugated antibody  (Bio-Techne corporation)
95
Bio-Techne corporation mouse/rat cd31/pecam-1 alexa fluor® 488-conjugated antibody
Glioma‐intrinsic HEXB promoted Endo‐MT changes of ECs. (A) Survival of GBM patients received bevacizumab treatment with different HEXB expression in GSE79671 (log‐rank test). (B) Survival of GBM patients received bevacizumab treatment with different HEXB expression in GSE72951 (log‐rank test). (C) The rate of response patients was lower in GBM patients with high HEXB expression in GSE72951 (Patients with a survival time superior to the median survival of the standard treatment were defined as the responder group, whereas those with a shorter survival time were defined as the non‐responder group). (D) The analysis of migration ability of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (E) Permeability changes of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (F) Immunofluorescence staining image of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (G) Western blot results of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (H) PCR results of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (I) Flow cytometry of <t>CD31</t> + cells in tumors from GSC1‐bearing mice. (J) Flow cytometry of CD31 + cells in tumors from GSC21‐bearing mice. (Date were presented as means ± standard deviations, * indicates p ≤ 0.05, ** indicates p < 0.01, **** indicates p < 0.0001.).
Mouse/Rat Cd31/Pecam 1 Alexa Fluor® 488 Conjugated Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd31+mouse/Mouse%2FRat+CD31%2FPECAM-1+Alexa+Fluor%C2%AE+488-conjugated+Antibody/custom%40fab3628g%4042441406
Average 95 stars, based on 1 article reviews
mouse/rat cd31/pecam-1 alexa fluor® 488-conjugated antibody - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
anti cd31 antibody  (R&D Systems)
98
R&D Systems anti cd31 antibody
Glioma‐intrinsic HEXB promoted Endo‐MT changes of ECs. (A) Survival of GBM patients received bevacizumab treatment with different HEXB expression in GSE79671 (log‐rank test). (B) Survival of GBM patients received bevacizumab treatment with different HEXB expression in GSE72951 (log‐rank test). (C) The rate of response patients was lower in GBM patients with high HEXB expression in GSE72951 (Patients with a survival time superior to the median survival of the standard treatment were defined as the responder group, whereas those with a shorter survival time were defined as the non‐responder group). (D) The analysis of migration ability of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (E) Permeability changes of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (F) Immunofluorescence staining image of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (G) Western blot results of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (H) PCR results of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (I) Flow cytometry of <t>CD31</t> + cells in tumors from GSC1‐bearing mice. (J) Flow cytometry of CD31 + cells in tumors from GSC21‐bearing mice. (Date were presented as means ± standard deviations, * indicates p ≤ 0.05, ** indicates p < 0.01, **** indicates p < 0.0001.).
Anti Cd31 Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd31+mouse/Human%2FMouse%2FRat+CD31%2FPECAM-1+Antibody/pmc13621939-56-29-31
Average 98 stars, based on 1 article reviews
anti cd31 antibody - by Bioz Stars, 2026-10
98/100 stars
  Buy from Supplier
updated february 2025 goat anti cd31  (R&D Systems)
98
R&D Systems updated february 2025 goat anti cd31
Glioma‐intrinsic HEXB promoted Endo‐MT changes of ECs. (A) Survival of GBM patients received bevacizumab treatment with different HEXB expression in GSE79671 (log‐rank test). (B) Survival of GBM patients received bevacizumab treatment with different HEXB expression in GSE72951 (log‐rank test). (C) The rate of response patients was lower in GBM patients with high HEXB expression in GSE72951 (Patients with a survival time superior to the median survival of the standard treatment were defined as the responder group, whereas those with a shorter survival time were defined as the non‐responder group). (D) The analysis of migration ability of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (E) Permeability changes of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (F) Immunofluorescence staining image of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (G) Western blot results of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (H) PCR results of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (I) Flow cytometry of <t>CD31</t> + cells in tumors from GSC1‐bearing mice. (J) Flow cytometry of CD31 + cells in tumors from GSC21‐bearing mice. (Date were presented as means ± standard deviations, * indicates p ≤ 0.05, ** indicates p < 0.01, **** indicates p < 0.0001.).
Updated February 2025 Goat Anti Cd31, supplied by R&D Systems, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd31+mouse/Human%2FMouse%2FRat+CD31%2FPECAM-1+Antibody/pm42809441-78-0-6
Average 98 stars, based on 1 article reviews
updated february 2025 goat anti cd31 - by Bioz Stars, 2026-10
98/100 stars
  Buy from Supplier
cd31 pecam 1  (R&D Systems)
98
R&D Systems cd31 pecam 1
Glioma‐intrinsic HEXB promoted Endo‐MT changes of ECs. (A) Survival of GBM patients received bevacizumab treatment with different HEXB expression in GSE79671 (log‐rank test). (B) Survival of GBM patients received bevacizumab treatment with different HEXB expression in GSE72951 (log‐rank test). (C) The rate of response patients was lower in GBM patients with high HEXB expression in GSE72951 (Patients with a survival time superior to the median survival of the standard treatment were defined as the responder group, whereas those with a shorter survival time were defined as the non‐responder group). (D) The analysis of migration ability of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (E) Permeability changes of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (F) Immunofluorescence staining image of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (G) Western blot results of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (H) PCR results of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (I) Flow cytometry of <t>CD31</t> + cells in tumors from GSC1‐bearing mice. (J) Flow cytometry of CD31 + cells in tumors from GSC21‐bearing mice. (Date were presented as means ± standard deviations, * indicates p ≤ 0.05, ** indicates p < 0.01, **** indicates p < 0.0001.).
Cd31 Pecam 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd31+mouse/Human%2FMouse%2FRat+CD31%2FPECAM-1+Antibody/pm42788754-43-30-32
Average 98 stars, based on 1 article reviews
cd31 pecam 1 - by Bioz Stars, 2026-10
98/100 stars
  Buy from Supplier
microvessels  (R&D Systems)
98
R&D Systems microvessels
Glioma‐intrinsic HEXB promoted Endo‐MT changes of ECs. (A) Survival of GBM patients received bevacizumab treatment with different HEXB expression in GSE79671 (log‐rank test). (B) Survival of GBM patients received bevacizumab treatment with different HEXB expression in GSE72951 (log‐rank test). (C) The rate of response patients was lower in GBM patients with high HEXB expression in GSE72951 (Patients with a survival time superior to the median survival of the standard treatment were defined as the responder group, whereas those with a shorter survival time were defined as the non‐responder group). (D) The analysis of migration ability of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (E) Permeability changes of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (F) Immunofluorescence staining image of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (G) Western blot results of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (H) PCR results of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (I) Flow cytometry of <t>CD31</t> + cells in tumors from GSC1‐bearing mice. (J) Flow cytometry of CD31 + cells in tumors from GSC21‐bearing mice. (Date were presented as means ± standard deviations, * indicates p ≤ 0.05, ** indicates p < 0.01, **** indicates p < 0.0001.).
Microvessels, supplied by R&D Systems, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd31+mouse/Human%2FMouse%2FRat+CD31%2FPECAM-1+Antibody/pm42785207-36-24-35
Average 98 stars, based on 1 article reviews
microvessels - by Bioz Stars, 2026-10
98/100 stars
  Buy from Supplier
pe cyanine7 antimouse cd31 antibody  (Elabscience Biotechnology)
94
Elabscience Biotechnology pe cyanine7 antimouse cd31 antibody
Glioma‐intrinsic HEXB promoted Endo‐MT changes of ECs. (A) Survival of GBM patients received bevacizumab treatment with different HEXB expression in GSE79671 (log‐rank test). (B) Survival of GBM patients received bevacizumab treatment with different HEXB expression in GSE72951 (log‐rank test). (C) The rate of response patients was lower in GBM patients with high HEXB expression in GSE72951 (Patients with a survival time superior to the median survival of the standard treatment were defined as the responder group, whereas those with a shorter survival time were defined as the non‐responder group). (D) The analysis of migration ability of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (E) Permeability changes of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (F) Immunofluorescence staining image of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (G) Western blot results of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (H) PCR results of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (I) Flow cytometry of <t>CD31</t> + cells in tumors from GSC1‐bearing mice. (J) Flow cytometry of CD31 + cells in tumors from GSC21‐bearing mice. (Date were presented as means ± standard deviations, * indicates p ≤ 0.05, ** indicates p < 0.01, **** indicates p < 0.0001.).
Pe Cyanine7 Antimouse Cd31 Antibody, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd31+mouse/PE%2FCyanine7+Anti-Mouse+CD31+Antibody/10__1038_slash_s41467___026___78085___9-465-0-30
Average 94 stars, based on 1 article reviews
pe cyanine7 antimouse cd31 antibody - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
e ab f1180b anti mouse cd45 2 elabscience  (Elabscience Biotechnology)
92
Elabscience Biotechnology e ab f1180b anti mouse cd45 2 elabscience
Glioma‐intrinsic HEXB promoted Endo‐MT changes of ECs. (A) Survival of GBM patients received bevacizumab treatment with different HEXB expression in GSE79671 (log‐rank test). (B) Survival of GBM patients received bevacizumab treatment with different HEXB expression in GSE72951 (log‐rank test). (C) The rate of response patients was lower in GBM patients with high HEXB expression in GSE72951 (Patients with a survival time superior to the median survival of the standard treatment were defined as the responder group, whereas those with a shorter survival time were defined as the non‐responder group). (D) The analysis of migration ability of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (E) Permeability changes of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (F) Immunofluorescence staining image of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (G) Western blot results of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (H) PCR results of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (I) Flow cytometry of <t>CD31</t> + cells in tumors from GSC1‐bearing mice. (J) Flow cytometry of CD31 + cells in tumors from GSC21‐bearing mice. (Date were presented as means ± standard deviations, * indicates p ≤ 0.05, ** indicates p < 0.01, **** indicates p < 0.0001.).
E Ab F1180b Anti Mouse Cd45 2 Elabscience, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd31+mouse/Biotin+Anti-Mouse+CD31+Antibody/pm42773266-850-85-88
Average 92 stars, based on 1 article reviews
e ab f1180b anti mouse cd45 2 elabscience - by Bioz Stars, 2026-10
92/100 stars
  Buy from Supplier
cd31  (R&D Systems)
98
R&D Systems cd31
ID tissue exhibits higher densities of fibroblasts, macrophages, and microvessels compared to SC tissue. Immunofluorescence analysis comparing the expression of Vimentin (a fibroblast marker), CD68 (a macrophage marker), and <t>CD31</t> (an endothelial cell marker) in ID and SC tissues. For each group, n = 3; data represent mean ± s.d.; ∗P < 0.05 and ∗∗P < 0.01.
Cd31, supplied by R&D Systems, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd31+mouse/Human%2FMouse%2FRat+CD31%2FPECAM-1+Antibody/pmc13091142-299-20-21
Average 98 stars, based on 1 article reviews
cd31 - by Bioz Stars, 2026-10
98/100 stars
  Buy from Supplier
magnetic microbeads miltenyi biotec  (Miltenyi Biotec)
96
Miltenyi Biotec magnetic microbeads miltenyi biotec
ID tissue exhibits higher densities of fibroblasts, macrophages, and microvessels compared to SC tissue. Immunofluorescence analysis comparing the expression of Vimentin (a fibroblast marker), CD68 (a macrophage marker), and <t>CD31</t> (an endothelial cell marker) in ID and SC tissues. For each group, n = 3; data represent mean ± s.d.; ∗P < 0.05 and ∗∗P < 0.01.
Magnetic Microbeads Miltenyi Biotec, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd31+mouse/CD31+MicroBeads%2C+mouse/pm42501329-276-41-43
Average 96 stars, based on 1 article reviews
magnetic microbeads miltenyi biotec - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier

Image Search Results


Glioma‐intrinsic HEXB promoted Endo‐MT changes of ECs. (A) Survival of GBM patients received bevacizumab treatment with different HEXB expression in GSE79671 (log‐rank test). (B) Survival of GBM patients received bevacizumab treatment with different HEXB expression in GSE72951 (log‐rank test). (C) The rate of response patients was lower in GBM patients with high HEXB expression in GSE72951 (Patients with a survival time superior to the median survival of the standard treatment were defined as the responder group, whereas those with a shorter survival time were defined as the non‐responder group). (D) The analysis of migration ability of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (E) Permeability changes of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (F) Immunofluorescence staining image of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (G) Western blot results of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (H) PCR results of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (I) Flow cytometry of CD31 + cells in tumors from GSC1‐bearing mice. (J) Flow cytometry of CD31 + cells in tumors from GSC21‐bearing mice. (Date were presented as means ± standard deviations, * indicates p ≤ 0.05, ** indicates p < 0.01, **** indicates p < 0.0001.).

Journal: Advanced Science

Article Title: Tumor‐Intrinsic HEXB Drives Endothelial‐To‐Mesenchymal Transition and Confers Resistance to Anti‐Angiogenic Therapy in Glioblastoma

doi: 10.1002/advs.78208

Figure Lengend Snippet: Glioma‐intrinsic HEXB promoted Endo‐MT changes of ECs. (A) Survival of GBM patients received bevacizumab treatment with different HEXB expression in GSE79671 (log‐rank test). (B) Survival of GBM patients received bevacizumab treatment with different HEXB expression in GSE72951 (log‐rank test). (C) The rate of response patients was lower in GBM patients with high HEXB expression in GSE72951 (Patients with a survival time superior to the median survival of the standard treatment were defined as the responder group, whereas those with a shorter survival time were defined as the non‐responder group). (D) The analysis of migration ability of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (E) Permeability changes of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (F) Immunofluorescence staining image of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (G) Western blot results of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (H) PCR results of HBMECs treated with different CM (sh#1: shHEXB#1; sh#2: shHEXB#2). (I) Flow cytometry of CD31 + cells in tumors from GSC1‐bearing mice. (J) Flow cytometry of CD31 + cells in tumors from GSC21‐bearing mice. (Date were presented as means ± standard deviations, * indicates p ≤ 0.05, ** indicates p < 0.01, **** indicates p < 0.0001.).

Article Snippet: The CD31 Microbeads (130‐097‐418, Miltenyi) were used for positive selection CD31 + endothelial cells from single‐cell suspensions of mouse tissues.

Techniques: Expressing, Analysis, Migration, Permeability, Immunofluorescence, Staining, Western Blot, Flow Cytometry

ID tissue exhibits higher densities of fibroblasts, macrophages, and microvessels compared to SC tissue. Immunofluorescence analysis comparing the expression of Vimentin (a fibroblast marker), CD68 (a macrophage marker), and CD31 (an endothelial cell marker) in ID and SC tissues. For each group, n = 3; data represent mean ± s.d.; ∗P < 0.05 and ∗∗P < 0.01.

Journal: Bioactive Materials

Article Title: Injection site dictates the immune response to a biodegradable polymer and corresponding collagen regeneration

doi: 10.1016/j.bioactmat.2026.04.004

Figure Lengend Snippet: ID tissue exhibits higher densities of fibroblasts, macrophages, and microvessels compared to SC tissue. Immunofluorescence analysis comparing the expression of Vimentin (a fibroblast marker), CD68 (a macrophage marker), and CD31 (an endothelial cell marker) in ID and SC tissues. For each group, n = 3; data represent mean ± s.d.; ∗P < 0.05 and ∗∗P < 0.01.

Article Snippet: After antigen retrieval and blocking, sections were incubated overnight at 4 °C with primary antibodies targeting vimentin, CD68 (ABclonal, A20803), CD31 (R&D SYSTEMS, AF3628), HMGB1 (Cell Signaling Technology, 3935), HSP70 (ABclonal, A23457), NF-κB p65 (ABclonal, A19653), CD206 (Cell Signaling Technology, 24595), and FAPα (ABclonal, A23789 ).

Techniques: Immunofluorescence, Expressing, Marker